Clinical trials
Locally Advanced Basal Cell Carcinoma clinical trials
Below are recruiting locally advanced basal cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 417 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07632079RecruitingPhase 2
Fast-Track Radiation and Chemotherapy for Esophageal Cancer
This study tests a shorter course of combined radiation therapy and chemotherapy (using drugs called paclitaxel and carboplatin) to treat esophageal cancer with the goal of curing it. The faster treatment schedule may help patients finish therapy sooner while still being effective.
AmsterdamAges 18 years+ - NCT05096390RecruitingPhase 2
Axitinib plus pembrolizumab for first metastatic kidney cancer
This Phase 2 trial studies whether combining axitinib and pembrolizumab can shrink and control metastatic or inoperable type 2 or mixed papillary kidney cancer. It may help by blocking cancer growth signals and boosting the immune system to attack the cancer.
AngersAges 18 years+ - NCT06496789RecruitingPhase 2
Immunotherapy plus chemo before surgery for stomach cancer
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
TianjinAges 18–75 - NCT07522151RecruitingPhase 3
Adebrelimab with Surgery for Stomach Cancer
This trial tests a new immunotherapy drug called adebrelimab combined with chemotherapy and surgery for stomach cancer or junction cancers (where the stomach meets the esophagus). The goal is to see if this treatment helps prevent cancer from coming back after surgery.
Beijing, Beijing MunicipalityAges 18–75 - NCT07114861RecruitingPhase 1/Phase 2
KN510713 with mFOLFIRINOX for advanced pancreatic cancer
This study tests a new drug (KN510713) combined with the standard chemotherapy mFOLFIRINOX for people with advanced pancreatic cancer that hasn't had prior chemotherapy. The goal is to see if adding the new drug can improve outcomes.
Goyang-siAges 19–75 - NCT07020247RecruitingPhase 3
Personalized radiation plus chemo with or without immunotherapy for rectal cancer
This trial tests adding immunotherapy to standard radiation and chemotherapy for patients with locally advanced rectal cancer. The goal is to see if a personalized approach improves outcomes while sparing more normal tissue.
Chengdu, SichuanAges 18 years+ - NCT06250036RecruitingPhase 2
Immunotherapy before surgery for MMRd stomach cancer
This trial tests two immunotherapy drugs, zimberelimab and domvanalimab, given before surgery for people with a specific type of stomach cancer (called MMRd/MSI-H). The goal is to see if these drugs can shrink the tumor and improve outcomes.
Cambridge, CambridgeshireAges 18 years+ - NCT05989425RecruitingPhase 2
Surufatinib before surgery for advanced thyroid cancer
This trial tests whether the drug Surufatinib, given before surgery, can shrink locally advanced or metastatic thyroid cancer. It's a targeted therapy that blocks blood vessels that feed tumors, and is given as a pill to see if it makes the cancer easier to remove.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07386704Enrolling by invitationPhase 2
Nimotuzumab with chemo and radiation for advanced pancreatic cancer
This trial tests adding nimotuzumab (a targeted antibody) to standard chemoradiation for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT05872685RecruitingPhase 2
Perioperative chemo plus serplulimab for specific stomach cancers
This Phase 2 trial tests whether adding serplulimab (an immune medicine) to standard chemotherapy before and/or around surgery can improve outcomes for people with certain locally advanced stomach cancer. You may get serplulimab or a placebo, and researchers will compare results to see if the immune add-on helps.
Hangzhou, ZhejiangAges 18–80 - NCT06234137Recruiting
Chemo plus targeted therapy for advanced HER2+ breast cancer
This trial tests a combination of chemotherapy (docetaxel and carboplatin) plus two targeted drugs (Inetetamab and Pyrotinib) for people with locally advanced HER2-positive breast cancer that has not spread to other parts of the body. The goal is to see if this powerful combo can shrink the tumor before surgery or other treatments.
Wenzhou, ZhejiangAges 18–75 - NCT07306286RecruitingPhase 2
Cryoablation plus immunotherapy for advanced pancreatic cancer
This trial tests combining cryoablation (freezing tumors) with a dual-antibody drug (PD-1/CTLA-4) for people whose locally advanced pancreatic cancer has stopped responding to first-line chemotherapy (AG regimen). The goal is to see if this combination can help control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05729646RecruitingPhase 2
Pre-surgery chemotherapy with toripalimab for dMMR stomach cancer
This trial studies whether adding toripalimab (an immune therapy) to chemotherapy before and around surgery can improve outcomes for people with certain mismatch repair–deficient stomach cancers. It mainly targets tumors that are dMMR and not HER2-positive.
Hangzhou, ZhejiangAges 18–80 - NCT06506292RecruitingPhase 2
Study of adebrelimab plus chemo before and after stomach cancer surgery
This trial tests combining adebrelimab (an immunotherapy) with chemotherapy (XELOX) before and after surgery for stomach cancer that hasn't spread. The goal is to see if this approach helps shrink tumors and improves outcomes.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07230639RecruitingPhase 2
Shorter radiation with chemo and immunotherapy for high-risk colon cancer
This trial tests a shorter course of radiation combined with chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of high-risk colon cancer that has not spread. The goal is to see if this approach can shrink the tumor before surgery and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06364371Recruiting
Predicting rectal cancer treatment response using multi-omics
This trial is testing a new way to predict how well your rectal cancer will respond to treatments given before surgery. It uses advanced tests (like looking at genes and other markers) to tailor your care.
Guangzhou, GuangdongAges 18–80 - NCT06705127RecruitingPhase 2
Radiation, chemo, and immunotherapy for HR+ breast cancer
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
Hangzhou, ZhejiangAges 18–75 - NCT05969171RecruitingPhase 2
Surufatinib plus chemotherapy for advanced pancreatic cancer
This Phase 2 study tests whether adding surufatinib to first-line treatment (either AG or a similar AG-based regimen) can improve outcomes for people with locally advanced or metastatic pancreatic cancer. You may be considered if your cancer cannot be removed by surgery and you’ve already had a short course of similar treatment with a response.
ShanghaiAges 18–75 - NCT06477991Recruiting
No surgery after immunotherapy for MSI-H colorectal cancer
This trial is studying whether some people with a specific type of advanced colorectal cancer (MSI-H/dMMR) might be able to skip surgery after immunotherapy. Doctors will use a blood test (MRD monitoring) to track the cancer, and then decide whether to keep an eye on it or operate.
Kunming, YunnanAges 18–75 - NCT07306273RecruitingPhase 2
Testing IRE and an immunotherapy drug for advanced pancreatic cancer
This trial tests a new combination: a special electric field treatment (IRE) plus a dual-function antibody (PD-1/CTLA-4) for people with locally advanced pancreatic cancer that didn't respond to standard chemotherapy. The goal is to see if this approach can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07026422RecruitingPhase 2
Combination immunotherapy with chemoradiation for high-risk rectal cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy and radiation before surgery for people with a specific type of high-risk rectal cancer. The goal is to see if adding these drugs can improve treatment results.
Jinan, ShandongAges 18–75 - NCT07026474RecruitingPhase 3
Re-radiation plus immunotherapy for recurrent head and neck cancer
This trial tests a combination of re-radiation and chemotherapy with the immunotherapy drug pembrolizumab for people whose head and neck cancer has come back after earlier treatment. It compares this approach to standard immunotherapy or chemo-immunotherapy, and may offer a new option for patients whose cancer has a specific marker (PD-L1).
ChemnitzAges 18 years+ - NCT07699939RecruitingPhase 2
Perioperative immunotherapy plus chemo for advanced gastric cancer
This trial tests whether adding the immunotherapy drug HLX10 (serplulimab) to standard chemotherapy (S-1 plus oxaliplatin) before and after surgery can improve outcomes for patients with advanced gastric or gastroesophageal junction cancer that has a high level of PD-L1 protein.
Chiba, ChibaAges 18–80 - NCT07104604RecruitingPhase 2
New combo before surgery for low rectal cancer
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
Shantou, GuangdongAges 18–75
Hear when a new Locally Advanced Basal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced basal cell carcinoma?
- Yes. Clin2 currently lists 417 recruiting locally advanced basal cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced basal cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced basal cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Advanced Clear Cell Renal Cell Carcinoma
- Locally Advanced Esophageal Squamous Cell Carcinoma
- Locally Advanced Lung Non-Small Cell Carcinoma
- Locally Advanced Merkel Cell Carcinoma
- Locally Advanced Oral Squamous Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
- Basal Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.